Royalty Pharma Stock Forecast, Price & News

-0.50 (-1.26 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.57 million shs
Average Volume2.46 million shs
Market Capitalization$23.80 billion
P/E Ratio24.50
Dividend Yield1.71%
30 days | 90 days | 365 days | Advanced Chart
Receive RPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

Royalty Pharma logo

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.65 out of 5 stars

Finance Sector

125th out of 2,047 stocks

Pharmaceutical Preparations Industry

21st out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 2.5Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Royalty Pharma (NASDAQ:RPRX) Frequently Asked Questions

Is Royalty Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Royalty Pharma stock.
View analyst ratings for Royalty Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Royalty Pharma?

Wall Street analysts have given Royalty Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Royalty Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Royalty Pharma?

Royalty Pharma saw a decrease in short interest in June. As of June 30th, there was short interest totaling 9,360,000 shares, a decrease of 30.3% from the June 15th total of 13,420,000 shares. Based on an average daily trading volume, of 1,880,000 shares, the short-interest ratio is currently 5.0 days. Approximately 3.1% of the shares of the company are short sold.
View Royalty Pharma's Short Interest

When is Royalty Pharma's next earnings date?

Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Royalty Pharma

How can I listen to Royalty Pharma's earnings call?

Royalty Pharma will be holding an earnings conference call on Wednesday, August 11th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) issued its earnings results on Tuesday, May, 11th. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The biopharmaceutical company had revenue of $524 million for the quarter, compared to the consensus estimate of $489.61 million. Royalty Pharma had a trailing twelve-month return on equity of 13.49% and a net margin of 44.35%.
View Royalty Pharma's earnings history

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma declared a quarterly dividend on Monday, July 19th. Stockholders of record on Friday, August 20th will be paid a dividend of $0.17 per share on Wednesday, September 15th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date is Thursday, August 19th.
View Royalty Pharma's dividend history

Is Royalty Pharma a good dividend stock?

Royalty Pharma pays an annual dividend of $0.68 per share and currently has a dividend yield of 1.71%. Royalty Pharma does not yet have a strong track record of dividend growth. The dividend payout ratio of Royalty Pharma is 42.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 21.59% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.
View Royalty Pharma's dividend history.

What price target have analysts set for RPRX?

1 brokers have issued 12-month price objectives for Royalty Pharma's stock. Their forecasts range from $51.00 to $51.00. On average, they anticipate Royalty Pharma's share price to reach $51.00 in the next twelve months. This suggests a possible upside of 30.1% from the stock's current price.
View analysts' price targets for Royalty Pharma
or view top-rated stocks among Wall Street analysts.

Who are Royalty Pharma's key executives?

Royalty Pharma's management team includes the following people:
  • Mr. Pablo Gerardo Legorreta, Founder, Chairman & CEO (Age 56, Pay $55.67M)
  • Mr. Terrance P. Coyne, Exec. VP & CFO
  • Dr. James Folmar Reddoch Ph.D., Exec. VP, Chief Scientific Officer and Co-Head of Research & Investments (Age 51, Pay $3.4M)
  • Mr. George Wingate Lloyd, Exec. VP of Investments & Gen. Counsel (Age 61, Pay $3.4M)
  • Mr. Christopher Hite, Vice Chairman & Exec. VP (Age 53, Pay $3.8M)
  • Dr. Marshall Urist M.D., Ph.D., Exec. VP and Co-Head of Research & Investments
  • Mr. Sandy Balkin Ph.D., Sr. VP of Strategy & Analytics
  • Ms. Sarah Cata, VP & Treasurer

Who are some of Royalty Pharma's key competitors?

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), (CRM) and Twilio (TWLO).

When did Royalty Pharma IPO?

(RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

What is Royalty Pharma's stock symbol?

Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."

How do I buy shares of Royalty Pharma?

Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Royalty Pharma's stock price today?

One share of RPRX stock can currently be purchased for approximately $39.20.

How much money does Royalty Pharma make?

Royalty Pharma has a market capitalization of $23.80 billion and generates $2.12 billion in revenue each year. The biopharmaceutical company earns $975.04 million in net income (profit) each year or $1.61 on an earnings per share basis.

When was Royalty Pharma founded?

Royalty Pharma was founded in 1996.

What is Royalty Pharma's official website?

The official website for Royalty Pharma is

Where are Royalty Pharma's headquarters?

Royalty Pharma is headquartered at 110 E 59th Street, New York NY, 10022.

How can I contact Royalty Pharma?

Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.